Draxis iodine kit gets FDA approval

Nov 21, 2005

Radiopharmaceutical developer Draxis Health reported that the Food and Drug Administration has approved its DraxImage division's new, larger format of its HiCon kit for the preparation of sodium iodide I-131 capsules and oral solution.

The new format was developed at the request of the firm's high-volume radiopharmacy customers in the U.S. and will serve to round out the existing line of DraxImage radioactive iodine I-131 products, according to the Mississauga, Ontario-based firm.

In a further strategic move to focus production activities, DraxImage has initiated a process that will see it discontinue the manufacture and sale of implantable brachytherapy seeds by December 15 this year as part of an orderly exit from the brachytherapy market, the company said.

By AuntMinnie.com staff writers
November 22, 2005

Temporary shutdown hurts Draxis Health’s Q3, November 3, 2005

Draxis taps Brazier as COO, October 4, 2005

Draxis posts Q2 rise, August 11, 2005

Draxis joins Nasdaq biotech index, May 16, 2005

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$